1
|
Gascón E, Calvo AC, Molina N, Zaragoza P, Osta R. Identifying Hub Genes and miRNAs Associated with Alzheimer's Disease: A Bioinformatics Pathway to Novel Therapeutic Strategies. Biomolecules 2024; 14:1641. [PMID: 39766348 PMCID: PMC11726968 DOI: 10.3390/biom14121641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2024] [Revised: 12/17/2024] [Accepted: 12/19/2024] [Indexed: 01/15/2025] Open
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder that mainly affects the elderly population. It is characterized by cognitive impairment and dementia due to abnormal levels of amyloid beta peptide (Aβ) and axonal Tau protein in the brain. However, the complex underlying mechanisms affecting this disease are not yet known, and there is a lack of standardized biomarkers and therapeutic targets. Therefore, in this study, by means of bioinformatics analysis, AD-affected brain tissue was analyzed using the GSE138260 dataset, identifying 612 differentially expressed genes (DEGs). Functional analysis revealed 388 upregulated DEGs associated with sensory perception and 224 downregulated DEGs linked to the regulation and modulation of synaptic processes. Protein-protein interaction network analysis identified 20 hub genes. Furthermore, miRNA target gene networks revealed 1767 miRNAs linked to hub genes, among which hsa-mir-106a-5p, hsa-mir-17-5p, hsa-mir-26a-5p, hsa-mir-27a-3p and hsa-mir-34a-5p were the most relevant. This study presents novel biomarkers and therapeutic targets for AD by analyzing the information obtained with a comprehensive literature review, providing new potential targets to study their role in AD.
Collapse
Affiliation(s)
- Elisa Gascón
- Department of Anatomy, Embryology and Animal Genetics, University of Zaragoza, 50013 Zaragoza, Spain; (E.G.); (A.C.C.); (P.Z.)
- Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Av. Monforte de Lemos 3-5, 28029 Madrid, Spain
- Agroalimentary Institute of Aragon (IA2), University of Zaragoza, 50013 Zaragoza, Spain
- Institute of Health Research of Aragon (IIS), Av. San Juan Bosco 13, 50009 Zaragoza, Spain
| | - Ana Cristina Calvo
- Department of Anatomy, Embryology and Animal Genetics, University of Zaragoza, 50013 Zaragoza, Spain; (E.G.); (A.C.C.); (P.Z.)
- Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Av. Monforte de Lemos 3-5, 28029 Madrid, Spain
- Agroalimentary Institute of Aragon (IA2), University of Zaragoza, 50013 Zaragoza, Spain
- Institute of Health Research of Aragon (IIS), Av. San Juan Bosco 13, 50009 Zaragoza, Spain
| | - Nora Molina
- Department of Anatomy, Embryology and Animal Genetics, University of Zaragoza, 50013 Zaragoza, Spain; (E.G.); (A.C.C.); (P.Z.)
- Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Av. Monforte de Lemos 3-5, 28029 Madrid, Spain
- Agroalimentary Institute of Aragon (IA2), University of Zaragoza, 50013 Zaragoza, Spain
- Institute of Health Research of Aragon (IIS), Av. San Juan Bosco 13, 50009 Zaragoza, Spain
| | - Pilar Zaragoza
- Department of Anatomy, Embryology and Animal Genetics, University of Zaragoza, 50013 Zaragoza, Spain; (E.G.); (A.C.C.); (P.Z.)
- Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Av. Monforte de Lemos 3-5, 28029 Madrid, Spain
- Agroalimentary Institute of Aragon (IA2), University of Zaragoza, 50013 Zaragoza, Spain
- Institute of Health Research of Aragon (IIS), Av. San Juan Bosco 13, 50009 Zaragoza, Spain
| | - Rosario Osta
- Department of Anatomy, Embryology and Animal Genetics, University of Zaragoza, 50013 Zaragoza, Spain; (E.G.); (A.C.C.); (P.Z.)
- Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Av. Monforte de Lemos 3-5, 28029 Madrid, Spain
- Agroalimentary Institute of Aragon (IA2), University of Zaragoza, 50013 Zaragoza, Spain
- Institute of Health Research of Aragon (IIS), Av. San Juan Bosco 13, 50009 Zaragoza, Spain
| |
Collapse
|
2
|
Ono K. Signal Peptides and Their Fragments in Post-Translation: Novel Insights of Signal Peptides. Int J Mol Sci 2024; 25:13534. [PMID: 39769297 PMCID: PMC11678238 DOI: 10.3390/ijms252413534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2024] [Revised: 12/16/2024] [Accepted: 12/16/2024] [Indexed: 01/11/2025] Open
Abstract
Signal peptides (SPs), peptide sequences located at the N-terminus of newly synthesized proteins, are primarily known for their role in targeting proteins to the endoplasmic reticulum (ER). It has traditionally been assumed that cleaved SPs are rapidly degraded and digested near the ER. However, recent evidence has demonstrated that cleaved SP fragments can be detected in extracellular fluids such as blood flow, where they exhibit bioactivity. In addition, SP fragments are delivered to extracellular fluids via extracellular vesicles such as exosomes and microvesicles, which are important mediators of intercellular communication. These findings suggest that SPs and their fragments may have physiological roles beyond their classical function. This review aims to provide a comprehensive overview of these novel roles and offer new insights into the potential functions of SPs and their fragments in post-translational regulation and intercellular communication.
Collapse
Affiliation(s)
- Kenji Ono
- Department of Neurotoxicology, Graduate School of Medical Sciences and Medical School, Nagoya City University, Nagoya 467-8601, Japan; ; Tel.: +81-52-853-8992; Fax: +81-52-853-8996
- Department of Brain Function, Division of Stress Adaptation and Protection, Research Institute of Environmental Medicine, Nagoya University, Nagoya 464-8601, Japan
- Department of Molecular Pharmacokinetics, Nagoya University Graduate School of Medicine, Nagoya 464-8601, Japan
| |
Collapse
|
3
|
Pirhaghi M, Mamashli F, Moosavi-Movahedi F, Arghavani P, Amiri A, Davaeil B, Mohammad-Zaheri M, Mousavi-Jarrahi Z, Sharma D, Langel Ü, Otzen DE, Saboury AA. Cell-Penetrating Peptides: Promising Therapeutics and Drug-Delivery Systems for Neurodegenerative Diseases. Mol Pharm 2024; 21:2097-2117. [PMID: 38440998 DOI: 10.1021/acs.molpharmaceut.3c01167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2024]
Abstract
Currently, one of the most significant and rapidly growing unmet medical challenges is the treatment of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). This challenge encompasses the imperative development of efficacious therapeutic agents and overcoming the intricacies of the blood-brain barrier for successful drug delivery. Here we focus on the delivery aspect with particular emphasis on cell-penetrating peptides (CPPs), widely used in basic and translational research as they enhance drug delivery to challenging targets such as tissue and cellular compartments and thus increase therapeutic efficacy. The combination of CPPs with nanomaterials such as nanoparticles (NPs) improves the performance, accuracy, and stability of drug delivery and enables higher drug loads. Our review presents and discusses research that utilizes CPPs, either alone or in conjugation with NPs, to mitigate the pathogenic effects of neurodegenerative diseases with particular reference to AD and PD.
Collapse
Affiliation(s)
- Mitra Pirhaghi
- Department of Biological Sciences, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan 6673145137, Iran
- Institute of Biochemistry and Biophysics, University of Tehran, Tehran 1417614335, Iran
| | - Fatemeh Mamashli
- Institute of Biochemistry and Biophysics, University of Tehran, Tehran 1417614335, Iran
| | | | - Payam Arghavani
- Institute of Biochemistry and Biophysics, University of Tehran, Tehran 1417614335, Iran
| | - Ahmad Amiri
- Institute of Biochemistry and Biophysics, University of Tehran, Tehran 1417614335, Iran
| | - Bagher Davaeil
- Institute of Biochemistry and Biophysics, University of Tehran, Tehran 1417614335, Iran
| | - Mahya Mohammad-Zaheri
- Institute of Biochemistry and Biophysics, University of Tehran, Tehran 1417614335, Iran
| | - Zahra Mousavi-Jarrahi
- Institute of Biochemistry and Biophysics, University of Tehran, Tehran 1417614335, Iran
| | - Deepak Sharma
- Council of Scientific and Industrial Research-Institute of Microbial Technology, Chandigarh 160036, India
- Academy of Scientific & Innovative Research, Ghaziabad, Uttar Pradesh 201002, India
| | - Ülo Langel
- Department of Biochemistry and Biophysics, Stockholm University, Stockholm 10691, Sweden
| | - Daniel Erik Otzen
- Interdisciplinary Nanoscience Centre (iNANO), Aarhus University, 8000 Aarhus C 1592-224, Denmark
| | - Ali Akbar Saboury
- Institute of Biochemistry and Biophysics, University of Tehran, Tehran 1417614335, Iran
| |
Collapse
|